Black Rock Inc. Sorrento Therapeutics, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.74 - $1.83 $3.88 Million - $9.6 Million	5,244,074 Added 15.34%	39,423,641 $35.1 Million
Q3 2022 Nov 14, 2022	BUY	$1.51 - $2.88 $345,805 - $659,548	229,010 Added 0.67%	34,179,567 $53.7 Million
Q2 2022 Aug 12, 2022	BUY	$1.24 - $2.33 $14.8 Million - $27.8 Million	11,915,668 Added 54.08%	33,950,557 $68.2 Million
Q1 2022 May 12, 2022	BUY	$2.0 - $4.9 $518,048 - $1.27 Million	259,024 Added 1.19%	22,034,889 $51.3 Million
Q4 2021 Feb 10, 2022	BUY	$4.65 - $7.23 $4.22 Million - $6.57 Million	908,194 Added 4.35%	21,775,865 $101 Million
Q3 2021 Nov 09, 2021	BUY	$7.41 - $10.99 $13 Million - $19.2 Million	1,749,749 Added 9.15%	20,867,671 $159 Million
Q2 2021 Aug 11, 2021	BUY	$6.35 - $10.0 $121 Million - $191 Million	19,117,922 New	19,117,922 $185 Million

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.